Riskpilot← Back to searchSign inGet full accessOrocidin A/S
A/SActiveCVR 44348845Vandtårnsvej 62A, 1. bManufacture of pharmaceutical preparations · NACE 2120Est. 20231 employeeswww.orocidin.com
Revenue 2025
DKK -1,4M
EBITDA margin
100.0%
Equity ratio
31.6%
Financial strength
Net profit 2025
DKK -1,4M
1 employees
| Revenue | DKK -1,4M | — |
| EBITDA | DKK -1,4M | — |
| Net profit | DKK -1,4M | — |
| Total assets | DKK 9,3M | — |
| Equity | DKK 2,9M | — |
| Employees | 1 | — |
Legal name
Orocidin A/S
CVR number
44348845
Legal form
Aktieselskab
NACE code
2120 · Manufacture of pharmaceutical preparations
Founded
2. oktober 2023
Share capital
DKK 565.034
Employees
1 (FTE)
VAT registered
Yes
Audit selected
Yes
Last report
2025-03-31
Financial year
January – December
Signatory rights
Selskabet tegnes af direktøren i forening med bestyrelsesformanden eller af den samlede bestyrelse.
Company purpose
Selskabets formål er at udvikle repositionerede lægemidler samt dermed beslægtet virksomhed.
Address
Vandtårnsvej 62A, 1. b
Phone
+4542901733
Email
info@orocidin.com
Website
www.orocidin.com
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2025 |
|---|---|
| Revenue | -1.351 |
| Staff expenses | -0 |
| EBITDA | -1.351 |
| Depreciation & amort. | -11 |
| EBIT | -1.362 |
| Net financials | -29 |
| Profit before tax | -1.391 |
| Tax | -0 |
| Net profit | -1.391 |
| Item | 2025 |
|---|---|
| Total assets | 9.320 |
| Equity | 2.941 |
| Long-term debt | 0 |
| Short-term debt | 6.379 |
| Total debt | 6.379 |
EBITDA margin
-135123200.0%
This company
15.8%
Market median
-855210227% vs market
20252025
Equity ratio
31.6%
This company
38.2%
Market median
+17% vs market
20252025
Return on equity
-47.3%
This company
18.4%
Market median
-357% vs market
20252025
Net profit margin
-139118300.0%
This company
8.1%
Market median
-1717509977% vs market
20252025
Asset turnover
-0.14×
This company
1.12×
Market median
-113% vs market
20252025
Debt / equity
2.17×
This company
0.62×
Market median
-250% vs market
20252025
- Annual report 2025Filed via CVR / Virk · Period 2023-10-02 – 2025-03-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
AT Management | Management | 2024 | — | — |
RC Management | Management | 2023 | — | — |
BL Unofficial title | Unofficial title | 2024 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2024 | — | — | |
| Board of Directors | 2025 | — | — | |
| Chairman | 2024 | — | — | |
| Board of Directors | 2024 | — | — | |
| Board of Directors | 2024 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 100.0% | 100.0% | 2024 | |
JE Pitzner Holding ApS | Company | 5.0% | 0.0% | 2024 |
GK PARTNERS ApS | Company | 50.0% | 50.0% | 2024 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Orocidin A/S also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Allan Traugott Wehnert | Management | 0 companies |
| Rasmus Christian Drewes Jensen | Management | 0 companies |
| Bo Lauritzen | Unofficial title | 0 companies |
| Samia Sofie Kappe | Board of Directors | 0 companies |
| Christian Torben Hill-Madsen | Board of Directors | 0 companies |
| Peter Severin Bach | Chairman | 0 companies |
| Henrik Rouf | Board of Directors | 0 companies |
| Henrik Keller | Board of Directors | 0 companies |